08.11.26 -- Cut Complexity Across Your RNA And Cell & Gene Therapy Workflow

Reducing immunogenic RNA byproducts while preserving yield is key for mRNA manufacturing. Optimized transcription and capping streamline processing, cut costs, and enable scalable workflows.

Aseptic fill‑finish services support parenteral drug products with formulation development, vial and prefilled syringe manufacturing, and integrated quality and regulatory support.

Cell‑free DNA simplifies mRNA production by removing bacterial risk, stabilizing polyA tails, and eliminating extra steps — delivering higher yields and cleaner workflows.

Structured process development enables scalable GMP adenovirus manufacturing with optimized performance, yield, process robustness, and control at commercial scale.

A risk-based framework for identity testing of ancillary raw materials in gene therapy is presented, with emphasis on implementation based on product contact, material classification, and manufacturing stage.

Are you in need of an experienced and flexible GMP service provider that can assist you with the development and clinical manufacturing of your gene or cell therapy with CMC support?

Maggie Chen, Senior Director, Manufacturing & MSAT, shares how partnering with the right CDMO is essential to gain access to manufacturing platforms that reduce cost and accelerate timelines.

Discover how the Alerion™ Microbubble Cell Separation System outperformed standard magnetic methods in T cell recovery, speed, and scalability — achieving higher cell quality with Akadeum’s innovative microbubble technology.

A single-vendor model for quality, regulatory, and safety services provides project management and cost-effective scalability. Hear how integrated solutions support market entry and growth.